Pharmaceutical composition for preventing or treating diabetes containing TENC1 expression or activity suppressor

Patent metadata

Field	Value
Publication number	US-9402856-B2
Application number	US-201314374086-A
Country	US
Kind code	B2
Filing date	Jan 14, 2013
Priority date	Jan 30, 2012
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1. The pharmaceutical composition according to the present invention, which is for preventing or treating diabetes or a complication of diabetes and comprises the TENC1 expression or activity suppressor as an active ingredient, can be expected to be widely usable in preventing and treating diabetes or a complication of diabetes since the pharmaceutical composition can effectively prevent the muscular dystrophy and reduction in sugar adsorption that occur due to reduction in IRS-1 by suppressing degradation of IRS-1 caused by TENC1.

First claim

The invention claimed is:

1. A method for treating type 2 diabetes or complications of type 2 diabetes comprising administering to a subject in need thereof a pharmaceutical composition comprising:
an inhibitor of expression of TENC1 (Tensin like C1 domain containing phosphatase) as an active ingredient, wherein the inhibitor of expression of TENC1 is an siRNA comprising a sequence of SEQ ID NO. 8 or SEQ ID NO. 9.

2. The method of claim 1 , wherein the TENC1 includes an amino acid sequence of SEQ ID NO. 1.

3. The method of claim 1 , wherein the TENC1 includes a PTPase (protein tyrosine phosphate) activity.

4. The method of claim 1 , wherein the TENC1 uses IRS-1 (insulin receptor substrate-1) as a substrate.

5. The method of claim 1 , wherein the complications of diabetes are selected from the group consisting of muscular atrophy, diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, heart disease, cancer, osteoporosis, renal disease, sexual dysfunction, skin disease, hypertension, arteriosclerosis, stroke, and atherosclerosis.

6. The method of claim 1 , wherein the method suppresses degradation of IRS-1 by TENC1.

7. The method of claim 1 , wherein the method suppresses IRS-1 dephosphorylation of TENC1.

Assignees

• Postech Academy-Industry Found

Inventors

• Ryu Sung Ho
• Koh A Ra
• Lee Mi Nam
• Jeong Hee Yoon
• Yang Yong Ryoul
• Suh Pann Ghill

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title